Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRETA trial of cabozantinib in pretreated advanced RET-rearranged non-small cell lung cancer
2018-002948-88Phase 2Terminated
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Alma Mater Studiorum – Università di Bologna. Primary endpoints: Objective response rate and Tumor response categories. Started Aug 2021; status: terminated.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2018-002948-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002948-88.